Synonyms: MSLN, CAK1
Anti-Mesothelin (BMS-986148) is a fully human IgG1 monoclonal antibody targeting mesothelin. It is used to synthesize antibody-drug conjugate (ADC). It has potential multimodal therapeutic strategies in patients with advanced solid tumors. MW :150 KD.
| Featured Inhibitors | Y-27632 Dihydrochloride SB431542 CHIR-99021 (Laduviglusib) RMC-7977 RMC-6236 (Daraxonrasib) MRTX1133 MG132 Z-VAD-FMK VT3989 IAG933 |
|---|
| Description |
Anti-Mesothelin (BMS-986148) is a fully human IgG1 monoclonal antibody targeting mesothelin. It is used to synthesize antibody-drug conjugate (ADC). It has potential multimodal therapeutic strategies in patients with advanced solid tumors. MW :150 KD.
|
References |
|---|
| Isotype | Human IgG1 |
|---|---|
| Source | CHO |
| Formulation | 100 mM Pro-Ac, 20mM Arg, pH5.0 |
| Storage (From the date of receipt) |
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles. |
*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|---|
| NCT06885697 | RECRUITING | Drug: cyclophosphamide|Drug: fludarabine | Mesothelioma; Neoplasms; Stomach Neoplasms; Pancreatic Neoplasms; Ovarian Neoplasms; Lung Neoplasms; Thymus Neoplasms; Colonic Neoplasms | National Cancer Institute (NCI) | 2025-07-08 | PHASE1 |
| NCT07010523 | RECRUITING | Drug: Fludarabine|Drug: Cyclophosphamide | Mesothelin-positive Advanced Malignant Solid Tumors | First Affiliated Hospital of Zhejiang University | 2024-10-15 | |
| NCT05848999 | UNKNOWN | Mesothelin-positive Advanced Malignant Solid Tumors | Zhejiang University | 2023-04-27 | PHASE1 | |
| NCT05531708 | WITHDRAWN | Drug: Fludarabine|Drug: Cyclophosphamide | Mesothelin-positive Advanced Refractory Solid Tumors | Shanghai Pudong Hospital | 2021-04-02 | PHASE1 |
| NCT05783089 | NOT_YET_RECRUITING | Mesothelin-positive Advanced Malignant Solid Tumors | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | 2023-04 | PHASE1 | |
| NCT05775666 | UNKNOWN | Solid Tumor | Peking University | 2023-03 | PHASE1 |
(data from https://clinicaltrials.gov, updated on 2026-08-26)
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.